GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

GILEAD SCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$153.07−3.12 (-2.00%)

Close on Oct 19, 2026

Market cap: $190.27B
P/E (TTM): –
Dividend yield: 2.06%

GILEAD SCIENCES, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	29,443	28,754	27,116	27,281	27,305	24,689	22,449	22,127	26,107	30,390	32,639	24,890	11,202	9,702	8,385	7,949	7,011	5,336	4,230
Cost of Revenue	6,234	6,251	6,498	5,657	6,601	4,572	4,675	4,853	4,371	4,261	4,006	3,788	2,859	2,471	2,124	1,870	1,596	1,127	769
Gross Profit	23,209	22,503	20,618	21,624	20,704	20,117	17,774	17,274	21,736	26,129	28,633	21,102	8,343	7,231	6,261	6,080	5,416	4,209	3,461
Research & Development	5,799	5,907	5,718	4,977	4,601	4,927	4,055	3,920	3,734	5,098	3,014	2,854	2,120	1,760	1,229	1,073	940	722	591
Selling, General & Admin	5,774	6,091	6,090	5,673	5,246	5,151	4,381	4,056	3,878	3,398	3,426	2,983	1,699	1,461	1,242	1,044	947	797	706
Advertising Expenses	1,000	869	826	778	735	795	784	587	600	618	601	393	216	160	117	117	108	96	–
Total Costs & Expenses	19,421	27,092	19,511	19,951	17,387	20,618	18,162	13,927	11,983	12,757	10,446	9,625	6,678	5,692	4,596	3,987	3,482	2,657	2,066
Operating Income	10,022	1,662	7,605	7,330	9,918	4,071	4,287	8,200	14,124	17,633	22,193	15,265	4,524	4,010	3,790	3,962	3,529	2,679	2,165
Interest Expense	1,024	977	944	935	1,001	984	995	1,077	1,118	964	688	412	307	361	205	109	70	65	63
Other Non-Operating Income	798	6.00	198	-581	-639	-1,418	1,868	676	523	428	154	3.00	-9.00	-37	67	60	42	59	110
Merger & Restructuring Charges	138	188	527	–	–	–	–	–	–	–	–	–	–	15	0	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	0	27	136	0	–	–
Gain (Loss) on Investments	451	-274	-167	-657	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	9,796	690	6,859	5,814	8,278	1,669	5,160	7,799	13,529	17,097	21,659	14,856	4,208	3,612	3,651	3,914	3,502	2,673	2,211
Income Tax Expense	1,286	211	1,247	1,248	2,077	1,580	-204	2,339	8,885	3,609	3,553	2,797	1,151	1,038	862	1,024	876	702	635
Net Income incl. Noncontrolling Interests	8,510	480	5,613	4,566	6,201	89	5,364	5,460	4,644	13,488	18,106	12,059	3,057	2,574	2,789	2,890	2,626	1,970	1,576
Minority Interest in Earnings	0	0	-52	-26	-24	-34	-22	5.00	16	-13	-2.00	-42	-18	-18	-15	-12	10	-8.56	-9.11
Net Income	8,510	480	5,665	4,592	6,225	123	5,386	5,455	4,628	13,501	18,108	12,101	3,075	2,592	2,804	2,901	2,636	1,979	1,585
EPS (Basic)(per share)	6.84	0.38	4.54	3.66	4.96	0.10	4.24	4.20	3.54	10.08	12.37	7.95	2.01	1.71	1.81	1.69	1.46	1.08	0.86
EPS (Diluted)(per share)	6.78	0.38	4.50	3.64	4.93	0.10	4.22	4.17	3.51	9.94	11.91	7.35	1.81	1.64	1.77	1.66	1.41	1.03	0.82
Shares Outstanding (Basic, Weighted)(shares)	1,244	1,247	1,248	1,255	1,256	1,257	1,270	1,298	1,307	1,339	1,464	1,522	1,529	1,515	1,550	1,712	1,809	1,841	1,858
Shares Outstanding (Diluted, Weighted)(shares)	1,255	1,255	1,258	1,262	1,262	1,263	1,277	1,308	1,319	1,358	1,521	1,647	1,695	1,583	1,580	1,747	1,868	1,918	1,929
Dividend per Share(per share)	3.16	3.08	3.00	2.92	2.84	2.72	2.52	2.28	2.08	1.84	1.29	0.00	0.00	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.6%
Operating margin: -8.2%
Net margin: -10.6%
Return on equity, FY2025: 40.5%

Financial strength

Current ratio: 1.27
Debt to equity: 2.22
Debt to assets: 53.2%
Cash to current liabilities: 28.8%

Valuation

P/E ratio: –
Price to sales: 6.25
Price to book: 16.08
Dividend yield: 2.06%